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different pharmacokinetics of the protein product de-
pending on a variety of factors, including the vector, the
dose, the route of administration, the target organ, the
promoter, the transgene, and any antivector host defens-
es.1,2 The concept of pharmacokinetics of the protein
G ene transfer vectors, together with their promoter-transgene expression cassettes, can be considered
as drug delivery systems in which the protein product of
the transgene evokes the desired therapy. Like other
drug delivery systems, gene transfer vectors provide
Objective: Because of the relative inaccessibility of the heart for repeated
gene therapy, it would be useful to regulate the expression of transgenes
delivered in a single dose of a gene therapy vector. Incorporation into
the vector of a regulatable promoter that is responsive to pharmacolog-
ic agents that are widely used and well tolerated in clinical practice rep-
resents such a control strategy. Methods: A replication-deficient aden-
ovirus or an adeno-associated virus containing a chimeric promoter
composed of 5 glucocorticoid response elements and the murine throm-
bopoietin complementary DNA (AdGRE.mTPO or AAVGRE.mTPO)
was administered to the hearts of Sprague-Dawley rats. Platelet levels
were evaluated as a reporter of transgene activity with or without dex-
amethasone. For comparison, rats received a control adenovirus vector,
AdCMV.mTPO or AdCMV.Null, and the control adeno-associated virus
vector AAVCMV.luc, which encodes for the firefly luciferase (luc) gene.
Results: Platelet elevation in the AdGRE.mTPO group peaked 4 days
after dexamethasone administration, with a return to baseline 1 week
after the initial corticosteroid dose. Subsequent dexamethasone admin-
istration at 2 and 4 weeks resulted in similar but progressively decreased
responses. The AAVGRE.mTPO group had 5 peak platelet levels to a
minimum of 2.2-fold with respect to baseline without diminution with
subsequent dexamethasone administrations out to 169 days. In contrast,
the AdCMV.Null and AAVCMV.luc groups demonstrated no increase in
platelet counts and the AdCMV.mTPO group demonstrated a slow rise
to a single peak platelet count independent of dexamethasone adminis-
tration. Conclusion: It may be possible to control on demand the expres-
sion of a gene transferred to the heart. This strategy should be useful in
cardiac gene therapy. (J Thorac Cardiovasc Surg 1999;118:26-35)
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product is particularly critical in organs for which
administration of the gene transfer vector is cumber-
some or carries a risk to the recipient. The heart is one
such organ.
Although the heart is accessible for gene transfer by
direct intramyocardial injection from the epicardial or
endocardial surfaces and through the coronary arter-
ies,3-6 such transfers are invasive procedures that are
usually not performed repetitively in a given patient. In
the context of these considerations and the increasing
interest in cardiac gene transfer for the treatment of
coronary vascular insufficiency and the treatment of
heart failure, it is desirable to have a repertoire of car-
diac gene transfer strategies that exhibit different phar-
macokinetics of the protein product coded by the trans-
gene in the vector expression cassette.
One strategy to achieve different pharmacokinetics of
the transgene product is through controlling expression
of the transgene with different promoters. In this con-
text, the purpose of this study was to compare gene
expression patterns after intramyocardial gene transfer
of an expression cassette with an active constitutive
promoter to a cassette with a promoter that is regulated
by administration of an exogenous drug. To accomplish
this, we used adenovirus (Ad) and adeno-associated
virus (AAV) vectors to transfer the expression cas-
settes, because Ad and AAV vectors efficiently transfer
expression cassettes to cardiac myocytes after direct
intramyocardial administration of the vector.5,6 For the
constitutive promoter we used the cytomegalovirus
(CMV) early-intermediate promoter-enhancer7 and for
the regulatable promoter we used a chimeric promoter
containing multiple tandem glucocorticoid response
elements (GREs), a promoter responsive to systemical-
ly administered glucocorticoids.8,9 For the transgene
we used the murine thrombopoietin (mTPO) comple-
mentary DNA because of the ability of the secreted
thrombopoietin to induce a rise in blood platelet levels,
a reporter system that permits repetitive measurement
in the same experimental animal with a minimal
amount of blood sampled and minimizes interanimal
variability in response to expression of the transgene.9
The data demonstrate very different transgene product
pharmacokinetics after in vivo intramyocardial expres-
sion cassette transfer with a constitutive promoter and
a regulatable promoter, differences that may be exploit-
ed for different cardiac gene transfer applications.
Methods
Gene-transfer vectors. Three Ad vectors were used for the
study; all were based on the Ad5 backbone with deletions of
E1 and E3 and the expression cassette in the E1 region. Both
the CMV.mTPO and GRE.mTPO expression cassettes in Ad
vectors have been characterized in other organ systems. The
AdCMV.mTPO vector expresses the murine thrombopoietin
complementary DNA under control of the constitutive
cytomegalovirus early-intermediate promoter-enhancer.7 The
AdGRE.mTPO vector is identical to the AdCMV.mTPO vec-
tor except that the mTPO complementary DNA is under con-
trol of the chimeric GRE promoter that uses 5 GREs from the
rat tyrosine aminotransferase gene in tandem with the inser-
tion of Ad2 major late promoter TATA box–initiation site8,9
(Fig 1). The AdCMV.Null vector, which served as a negative
control, is identical to the AdCMV.mTPO vector but contains
no transgene in the expression cassette.10 All the Ad vectors
were purified by cesium chloride density gradient ultracen-
trifugation, titered by plaque-forming assay on 293 cells, and
demonstrated to be free of replication competent Ad.11,12
The AAV vector AAVCMV.luc included the AAV terminal
repeats and an expression cassette of the cytomegalovirus
early/intermediate promoter-enhancer and the luciferase (luc)
reporter gene. The proviral plasmid pAAVCMV.luc was con-
structed by ligating the XhoI-SalI fragment of pTRUF2 con-
taining the AAV terminal repeats and the CMV promoter with
the XhoI-SalI fragment of pGL2-Basic containing the
luciferase complementary DNA and the simian virus 40
polyadenylic acid stop signal (Promega Corporation,
Madison, Wis). The pAAVGRE.mTPO was constructed by
inserting into the AAV backbone, the BglII-digested pTRUF2
Fig 1. Expression cassette with chimeric GRE promoter (5xGRE) including 5 GREs from the rat tyrosine amino-
transferase gene inserted upstream of Ad-2 major late promoter (Ad2MLP)8 with mTPO complementary DNA as
reporter gene and simian virus 40 (SV40) polyadenylic acid (poly A) stop signal.9
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fragment, with the XbaI fragment from the pGRE.mTPO9
containing the mouse thrombopoietin complementary DNA
driven by the dexamethasone-inducible GRE5 promoter (Fig
1). AAV vectors were produced by transfecting 293 human
embryonic kidney cells (American Type Culture Collection,
Manassas, Va) with a mixture of 3 plasmids: an AAV proviral
plasmid, pACG2 (containing the AAV rep and cap genes), and
pXX6 (containing the Ad E2A, E4, and VA genes). The result-
ing virions were purified with a cesium chloride gradient fol-
lowed by dialysis in phosphate-buffered saline solution, pH
7.4.13 The activities of the AAV vectors in infectious units (iu)
were determined by a replication center assay.14
Experimental design. Male Sprague-Dawley rats (250-
350 g) were from Charles River (Charles River Laboratories,
Inc, Wilmington, Mass) or Taconic (Germantown, NY). The
body weights of rats were matched for each experiment. Each
experiment included 3 animals for each data point represent-
ed. A total of 36 animals were used for this study (30 for
repetitive platelet evaluations and 6 for Northern analysis).
Evaluation of the in vivo responses to dexamethasone of
the constitutive CMV promoter and the inducible GRE pro-
moter was performed by administering the Ad vector
(AdCMV.mTPO, AdGRE.mTPO, AdCMV.Null all 109 plaque-
forming units [pfu]) and AAV vectors (AAVGRE.mTPO or
AAVCMV.luc, 109 iu) in a single apical myocardial injection
in the rats after a sternotomy under anesthesia.15 Animals
were sedated with an intraperitoneal injection of 80 mg/kg
ketamine and 5 mg/kg xylazine. Once an adequate plane of
anesthesia was accomplished the rats were intubated with a
20-gauge angiocatheter. A left parasternotomy was per-
formed with the assistance of a rodent ventilator (Harvard
Apparatus, Inc, Holliston, Mass), gaining full exposure to the
heart. An apical injection of vector was administered in a vol-
ume of 50 m L (vector diluted with phosphate-buffered saline
solution, pH 7.4; BioFluids, Rockville, Md). The chest was
closed in layers. Any remaining air in the thoracic cavity was
aspirated with an indwelling angiocatheter and 10-mL
syringe. Once the animals were spontaneously breathing, the
endotracheal tube was removed and the animals were allowed
to recover. No operative deaths were encountered in this
study. The AdCMV.mTPO group received no therapy (no
dexamethasone group) or 0.75 mg/d dexamethasone
intraperitoneally on 3 consecutive days after vector adminis-
tration. The AdGRE.mTPO and AdCMV.Null groups
received no therapy or 0.75 mg/d dexamethasone on 3 con-
secutive days after vector administration and starting days 17
and 31. The AAVGRE.mTPO and AAVCMV.luc groups
received no treatment or 0.75 mg/d dexamethasone on 3 con-
secutive days 7 days after vector administration and starting
on days 27, 34, 97, and 165 days. The animals were subse-
quently evaluated for expression of mTPO messenger RNA
levels and platelet levels as described here.
Northern analysis. The Ad vectors were used to evaluate
upward regulation of the mTPO complementary DNA in the
GRE.mTPO cassette transferred to the hearts of Sprague-
Dawley rats. The AdGRE.mTPO, AdCMV.mTPO, and
AdCMV.Null vectors were administered to the hearts of the
rats as described, with and without dexamethasone. Animals
were sacrificed 48 hours after vector administration and the
hearts were excised and homogenized. Total messenger RNA
(total 10 m g) was isolated with guanidine isothiocyanate phe-
nol-chloroform extraction,16 separated on a 1% agarose gel
Fig 2. Thrombopoietin messenger RNA levels assessed in heart (H) and liver (L) of animals 48 hours after
intramyocardial administration of AdCMV.mTPO, AdGRE.mTPO, or AdCMV.Null (each 109 pfu) with (+) and
without (–) concomitant systemic dexamethasone (Dex) therapy. Animals were sacrificed 48 hours after vector
administration and hearts and livers were excised and assessed for messenger RNA levels by Northern analysis.
GAPDH served as internal control for all lanes. Sizes of mTPO and GAPDH transcripts are indicated.
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containing 2.2 mol/L formaldehyde, transferred to a nylon
membrane (NYTRAN; Schleicher & Schuell, Inc, Keene,
NH), and hybridized with a phosphorus 32–labeled mTPO
complementary DNA probe and a control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) complementary DNA
probe17 prepared by random priming and evaluated by autora-
diography.18
Platelet levels. Platelet levels were determined in a blind-
ed fashion with a Neubauer hemocytometer (Fisher Scientific
Worldwide, Laboratory Projects Division, Springfield, NJ)
from blood samples drawn from the tail vein with a 20-m L
capillary pipette (Unopette; Fisher Scientific) 1 to 38 days
after Ad vector administration or 1 to 174 days after AAV
vector administration.
Statistical analysis. The results are expressed as mean ±
SEM. Statistical comparisons were made with the unpaired 2-
tailed Student t test.
Results
Northern analysis. In animals that received the
AdCMV.Null control vector no mTPO messenger RNA
was detectable in the heart or liver, independent of dex-
amethasone administration (Fig 2, lanes 5-8). Rats that
received the AdCMV.mTPO vector demonstrated 1.6-
kilobase (kb) mTPO messenger RNA transcripts in the
heart with or without dexamethasone (lanes 9 and 11).
No mTPO messenger RNA was detected in the liver,
independent of dexamethasone treatment (lanes 10 and
12). In contrast, in rats that received intramyocardial
AdGRE.mTPO 1.6-kb messenger RNA transcripts were
observed in the hearts of only dexamethasone-treated
animals (lane 3); no mTPO messenger RNA was detect-
ed in the hearts of rats that received AdGRE.mTPO
without concomitant dexamethasone treatment (lane 1).
No mTPO messenger RNA was observed in the livers of
animals that received the AdGRE.mTPO vector, inde-
pendent of dexamethasone treatment (lanes 2 and 4). In
all animals the control GAPDH messenger RNA was
expressed in heart and liver (lanes 1-12).
Platelet levels as a marker for murine throm-
bopoietin expression. Intracardiac administration of
the positive control vector AdCMV.mTPO evoked a
slow rise to a single peak platelet level at days 14 (with
dexamethasone) to 15 (no dexamethasone) after vector
administration, 6-fold higher than baseline platelet lev-
els (P < .005 for day 15 without dexamethasone com-
pared with baseline, P < .005 for day 14 with dexam-
ethasone; Fig 3). The same pattern of rise and fall of
blood platelet levels after AdCMV.mTPO administra-
tion was observed without dexamethasone or with dex-
amethasone administration, with a decline to baseline
Fig 3. Blood platelet levels after intramyocardial administration of AdCMV.mTPO vector alone or with con-
comitant administration of dexamethasone (Dex). Ad vector containing complementary DNA for mTPO driven
by CMV early promoter-enhancer (AdCMV.mTPO, 109 pfu) was injected into left ventricular walls of male
Sprague-Dawley rats. Animals were either treated intraperitoneally (ip) with 0.75 mg/d dexamethasone (filled tri-
angles) or received no treatment (open triangles) for 3 consecutive days beginning on day of vector administra-
tion (n = 3, each treatment group). Blood platelet levels were assessed at regular intervals from samples drawn
from tail vein. Data points represent mean of platelet counts (in 106 cells per microliter); error bars indicate SE.
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Fig 4. Blood platelet levels after intramyocardial administration of AdGRE.mTPO vector alone or with intermit-
tent administration of dexamethasone (Dex). Ad vector containing complementary DNA for mTPO driven by
GREs (AdGRE.mTPO, 109 pfu) injected into left ventricular walls of male Sprague-Dawley rats. Animals were
either treated intraperitoneally (ip) with 0.75 mg/d dexamethasone (filled squares) or received no treatment (open
squares) for 3 consecutive days beginning on day of vector administration (day 0), day 17, and day 31 (n = 3 for
each treatment group). Blood platelet levels were assessed at regular intervals from samples drawn from tail vein.
Data points represent mean of platelet counts (in 106 cells per microliter); error bars indicate SE.
Fig 5. Blood platelet levels after intramyocardial administration of AAVGRE.mTPO vector alone or with inter-
mittent administration of dexamethasone (Dex). AAV vector containing complementary DNA for mTPO driven
by GREs (AAVGRE.mTPO, 109 iu) was injected into left ventricular walls of male Sprague-Dawley rats. Animals
were either treated intraperitoneally (ip) with 0.75 mg/d dexamethasone (filled diamonds) or received no treat-
ment (open open diamonds) for 3 consecutive days beginning 7 days after vector administration and on days 27,
34, 97, and 165 (n = 3 for each treatment group). Blood platelet levels were assessed at regular intervals from
samples drawn from tail vein. Data points represent mean of platelet counts (in 106 cells per microliter); error
bars indicate SE.
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levels by day 38 (P > 0.2 for all comparisons at all time
points of dexamethasone with no dexamethasone).
To evaluate the hypothesis that upward regulation of
the GRE.mTPO expression cassette transferred to the
heart by the AdGRE.mTPO vector could be achieved
by intermittent administration of dexamethasone,
AdGRE.mTPO was given as a single intramyocardial
injection to male Sprague-Dawley rats with and with-
out intermittent dexamethasone stimulation. Dexa-
methasone was given intraperitoneally at 0.75 mg/d on
3 consecutive days beginning on the day of vector
administration (day 0) and on days 17 and 31. The
platelet levels increased concomitantly with dexam-
ethasone administration (Fig 4). Three peaks of blood
platelet levels were observed, each occurring 4 to 6
days after the initiation of dexamethasone therapy: day
5 (3-fold above baseline levels, P < .002 compared with
no dexamethasone), day 22 (2-fold above baseline lev-
els, P < .02 compared with no dexamethasone), and day
35 (1.5-fold above baseline levels, P < .04 compared
with no dexamethasone). All returned to baseline levels
within 1 week of dexamethasone administration (P >
.4, P > .2, and P > .4, respectively, all cycles of dexam-
ethasone administration compared with no dexametha-
sone). Although there was an increase in platelet levels
from baseline with each of the 3 cycles of dexametha-
sone administration in rats that received the
AdGRE.mTPO vector, the peak platelet levels gradual-
ly declined by the third cycle of dexamethasone admin-
istration (cycle 1 peak level on day 5 compared with
cycle 2 peak level on day 22, P > .1; cycle 2 peak level
on day 22 compared with cycle 3 peak level on day 35,
P > .08; cycle 1 peak level on day 5 compared with
cycle 3 peak level on day 35, P < .004).
To evaluate the hypothesis that long-term, repetitive
upward regulation of the GRE.mTPO expression cas-
sette transferred to the heart by the AAVGRE.mTPO
vector could be achieved by intermittent administration
of dexamethasone, AAVGRE.mTPO was given as a
single intramyocardial injection to male Sprague-
Dawley rats with and without intermittent dexametha-
sone stimulation. Dexamethasone was given intraperi-
toneally on 3 consecutive days at 0.75 mg/d beginning
7 days after vector administration and then again on
days 27, 34, 97, and 165. Five blood platelet level
peaks were observed (minimum of 2.2-fold above
baseline), each occurring 4 days after the initiation of
dexamethasone therapy (P < .0005 for each peak com-
Fig 6. Blood platelet levels after intramyocardial administration of the AdCMV.Null vector alone or with inter-
mittent administration of dexamethasone (Dex). A control Ad vector containing CMV early promoter-enhancer
but no transgene (AdCMV.Null, 109 pfu) was injected into left ventricular walls of male Sprague-Dawley rats.
Animals were either treated intraperitoneally (ip) with 0.75 mg/d dexamethasone (filled diamonds) or received no
treatment (open diamonds) for 3 consecutive days beginning on the day of vector administration (day 0), day 17,
and day 31 (n = 3, each treatment group). Blood platelet levels were assessed at regular intervals from samples
drawn from tail vein. Data points represent mean of platelet counts (in 106 cells per microliter); error bars indi-
cate SE.
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pared with no dexamethasone; Fig 5). In contrast to the
AdGRE.mTPO vector, there was no attenuation of the
platelet response to repetitive dexamethasone stimula-
tion as late as 169 days after vector administration.
The increases in blood platelet levels associated with
the administration of the AdGRE.mTPO or the AAV-
GRE.mTPO vector were not due to the dexamethasone
per se because intermittent administration of dexameth-
asone after intramyocardial administration of the nega-
tive control vectors (AdCMV.Null and AAVCMV.luc)
were not associated with increases in blood platelets
with respect to administration of those vectors without
concomitant administration of dexamethasone (P > .08
for comparisons at all time points of AdCMV.Null and
dexamethasone with AdCMV.Null but no dexametha-
sone, Fig 6; P > .2 for comparisons at all time points of
AAVCMV.luc and dexamethasone with AAVCMV.luc
but no dexamethasone, Fig 7).
Discussion
With the emergence of cardiac gene therapy strate-
gies and the increasing success of gene transfer to ani-
mals,1-5,19-21 several challenges arise in adapting such
strategies to clinical settings. The availability of vectors
with differing pharmacokinetics would allow custom
tailoring in the therapeutic armamentarium to meet the
needs of the cardiac disease processes in question. This
study demonstrates differing pharmacokinetics of AAV
and Ad vector–mediated myocardial transfer of the
same mTPO complementary DNA driven by different
promoters, the CMV constitutive early promoter-
enhancer and a regulatable chimeric GRE promoter.
Although the CMV promoter results in more effective
expression of the reporter complementary DNA, lead-
ing to a greater peak elevation of platelet levels inte-
grated across time, the GRE promoter has the advan-
tage of being exogenously controllable by a commonly
used pharmacologic agent once gene transfer to the
heart has been accomplished. The use of such a vector
could allow delayed or repetitive transgene expression
as dictated by clinical conditions.
One of the limitations of Ad-mediated gene transfer
is the relatively short duration of expression (weeks to
months).22 This is advantageous for angiogenesis
applications to limit the potential for promiscuous
angiogenesis or hemangioma formation23; for long-
term cardiac therapy strategies, however, Ad vectors
will have limited applications. To circumvent these
Fig 7. Blood platelet levels after intramyocardial administration of control AAVCMV.luc vector alone, or with
intermittent administration of dexamethasone (Dex). An AAV vector containing the complementary DNA for the
luciferase firefly gene containing the CMV early promoter/enhancer but no transgene (AAVCMV.luc, 109 iu) was
administered into the wall of the left ventricle of male Sprague-Dawley rats. Animals were either treated intraperi-
toneally (ip) with 0.75 mg/d dexamethasone (filled squares) or received no treatment (open squares) for 3 con-
secutive days beginning 7 days after vector administration, and on days 27, 34, 97, and 165 (n = 3 for each treat-
ment group). Blood platelet levels were assessed at regular intervals from samples drawn from tail vein. Data
points represent mean of platelet counts (in 106 cells per microliter); error bars indicate SE.
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limitations of Ad-mediated cardiac gene transfer, an
AAV vector with a regulatable promoter controllable
by exogenously administered pharmacologic agents
would afford the advantage of long-term regulatable
expression of a transgene once delivered to the heart,
thus allowing the clinician to custom tailor the thera-
peutic regimen to the patient’s clinical needs. These
applications could be useful in the treatment of such
chronic cardiac conditions as heart failure.
A variety of strategies have been devised to control in
vivo expression of transferred genes and thus alter the
pharmacokinetics of in vivo gene transfer vectors in the
context of regulatable or inducible promoters. Many of
these regulatable promoters use exogenously adminis-
tered agents to control transgene expression and some
use the physiologic milieu to control gene expression.
Examples of the exogenous control promoters include
the tetracycline-responsive promoter, a chimeric trans-
activator consisting of the DNA and tetracycline-bind-
ing domains from the bacterial tet repressor fused to the
transactivation domain of herpes simplex virion protein
1624; a chimeric promoter with multiple cyclic adeno-
sine monophosphate response elements superimposed
on a minimal fragment of the 5´-flanking region of the
cystic fibrosis transmembrane conductance regulator
gene25; the EGR1 radiation-inducible promoter26; and
the chimeric GRE promoter used in this study, with 5
GREs from the rat tyrosine aminotransferase gene in
tandem with the insertion of Ad2 major late promoter
TATA box–initiation site.9 Examples of the physiologic
control of promoters include a chimera of the thymi-
dine kinase promoter and the thyroid hormone and
retinoic acid–responsive element responsive to both
exogenous and endogenous tri-iodothyronine27; com-
plement factor 3 and serum amyloid A3 promoters
responsive to inflammatory stimuli28; the grp78 and
BiP stress-inducible promoter, a glucose-regulated pro-
tein that is inducible through glucose deprivation,
chronic anoxia, and acidic pH29; and hypoxia-inducible
factor 1 and a heterodimeric basic helix-loop-helix pro-
tein that activates transcription of the human erythro-
poietin gene in hypoxic cells, which has been shown to
act as a regulatable promoter in the context of gene
therapy in vivo.20
Finally, an interesting strategy of regulating gene
expression in Ad-mediated gene therapy is to use 2 sep-
arate replication-deficient vectors with the promoter of
the therapeutic gene, AdIL8.b gal (Escherichia coli
lacZ reporter gene controlled by the 5´ flanking region
of the human interleukin 8 gene, a promoter containing
elements responsive to tumor necrosis factor- a ) in vec-
tor 1 controlled by the product of the expression cas-
sette in vector 2, AdEGR1.TNF (used to direct the pro-
duction of tumor necrosis factor under the control of
the basal activity of the early growth response 1 pro-
moter).10
Whereas the highly active constitutive CMV promot-
er used in the AdCMV.mTPO vector demonstrated an
elevation in blood platelet levels, reaching peak levels
14 to 15 days after vector administration and returning
to baseline by day 38 independent of dexamethasone
administration, the chimeric GRE promoter in the
AdGRE.mTPO vector was responsive to intermittent
administration of dexamethasone with intermittent ele-
vations of blood platelet levels concomitant with dex-
amethasone stimulation. Although the peak blood
platelet levels progressively declined with each succes-
sive round of vector administration (probably as a
result of loss of the vector genome resulting from host
responses to the Ad vector22), these observations
demonstrated intermittent exogenous control of a gene
transferred to the heart. In the context of regulatable
expression, the AAVGRE.mTPO vector was responsive
to intermittent administration of dexamethasone with
intermittent elevations of blood platelet levels con-
comitant with dexamethasone stimulation, reaching
levels a minimum of 2.2-fold above baseline levels. In
sharp contrast to the Ad vector expressing the mTPO
transgene, which may be limited in terms of duration of
expression because of immune responses, the AAV
vector demonstrated persistent elevations of peak
platelet level to a minimum of 2.2-fold above baseline
levels with each successive round of dexamethasone
administration. In the context of cardiac gene therapy,
with the advent of better vectors, promoters, and an
expanding scope of disease processes amenable to gene
therapy strategies, vectors of differing pharmacokinet-
ics will be a useful means of controlling the timing and
duration of myocardial gene therapy. With this evi-
dence of the feasibility of regulatable expression of
transgenes delivered to the myocardium and with evi-
dence of the ability of vectors such as the AAV to pro-
vide long-term myocardial transgene expression,6 it is
conceivable with this vector technology that trans-
genes, such as that for vascular endothelial growth fac-
tor, not only could be delivered at the time of coronary
bypass but could be “turned on” months or even years
later, at the time of a threatened graft closure.
We thank N. Mohamed for help in preparing the manuscript.
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